Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29544738 | 1.00 | ALDH1A1 (0.42) | ALDH1A1CA9CA3CA6CA5A | |
| Hydrochloric Acid SCHEMBL1408624 | 0.98 | MAPT (0.41) | ALDH1A1CA9CA3CA6CA5A | |
| Hydrogen Sulfide SCHEMBL28200717 | 0.98 | MAPT (0.41) | ALDH1A1CA9CA3CA6CA5A | |
| Hydrochloric Acid SCHEMBL29502148 | 0.98 | MAPT (0.41) | ALDH1A1CA9CA3CA6CA5A | |
| Phosphine SCHEMBL28200789 | 0.98 | MAPT (0.41) | ALDH1A1CA9CA3CA6CA5A | |
| Bromide SCHEMBL20984147 | 0.98 | MAPT (0.41) | ALDH1A1CA9CA3CA6CA5A | |
| Oxalic Acid SCHEMBL20984172 | 0.88 | MAPT (0.46) | ALDH1A1CA9CA3CA6CA5A | |
| Phosphoric Acid SCHEMBL20984126 | 0.88 | MAPT (0.43) | ALDH1A1CA9CA3CA6CA5A | |
| Sulfuric Acid SCHEMBL20984178 | 0.88 | CA9 (0.44) | ALDH1A1CA9CA3CA6CA5A | |
| Nitric Acid SCHEMBL20984812 | 0.84 | ATM (0.43) | ALDH1A1CA9CA3CA6CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003160-B | Osthole hydrazone/acylhydrazone/sulfonylhydrazone derivatives, and preparation method and application thereof | 贵州中医药大学 | 2022-10-11 | — | — | CN | claimed |
| CN-110003160-A | A kind of Osthole hydrazone class/acylhydrazone class/sulphur acylhydrazone and preparation method thereof and application | 贵州中医药大学 | 2019-07-12 | — | — | CN | claimed |
| US-6797745-B1 | Hot melt inks containing styrene or terpene polymers | XEROX CORPORATION | 2004-09-28 | — | — | US | claimed |
| US-5897940-A | Ink jet transparencies | XEROX CORPORATION (US) | 1999-04-27 | — | — | US | claimed |
| US-5744273-A | Laminatable backing substrates containing fluoro compounds for improved toner flow | XEROX CORPORATION (US) | 1998-04-28 | — | — | US | claimed |
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-12497394-B2 | Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-12-16 | — | — | US | disclosed |
| US-12479857-B2 | Bax inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4587433-A1 | 3-(1H-INDOLE-2-CARBONYL)-6,6-DIMETHYL-N-((S)-1-OXO-3-((S)-2-OXOPYRROLIDIN-3-YL)P ROPAN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE-2-CARBOXAMIDE DERIVATIVES AS MPRO INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Takeda Pharmaceutical Company Limited (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12220401-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-11999734-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-06-04 | — | — | US | disclosed |
| US-5897940-A | Ink jet transparencies | XEROX CORPORATION (US) | 1999-04-27 | — | — | US | disclosed |
| US-5824699-A | COMPOUNDS FOR TREATMENT OF ARTHRITIS, COLORECTAL CANCER AND ALZHEIMER'S DISEASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-10-20 | — | — | US | disclosed |
| US-5776967-A | ANTIINFLAMMATORY AGENTS; THERAPY FOR ARTHRITIC DISORDERS, COLORECTAL CANCER AND ALZHEIMER'S DISEASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998004527-A1 | PYRANOINDOLE AND CARBAZOLE INHIBITORS OF COX-2 | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0682673-A4 | POROMERIC MATERIAL HAVING UNIFORMLY DISTRIBUTED ELECTRETS. | BUDINGER WILLIAM D (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0682673-A1 | POROMERIC MATERIAL HAVING UNIFORMLY DISTRIBUTED ELECTRETS | Budinger, William D (US) | 1995-11-22 | — | — | EP | disclosed |
| US-5384337-A | Poromeric material having uniformly distributed electrets for maintaining an electrostatic charge | BUDINGER WILLIAM D (US) | 1995-01-24 | — | — | US | disclosed |
| WO-1994018242-A1 | POROMERIC MATERIAL HAVING UNIFORMLY DISTRIBUTED ELECTRETS | BUDINGER WILLIAM D (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | BAX, BCL2, BAK1 | ALDH1A1 4585/4885CA9 1358/4885CA3 201/4885 |
| US-12220401-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | ALDH1A1 4454/4885CA9 3397/4885CA3 4462/4885 |
| US-11999734-B2 | Compounds and compositions for the treatment of cystic fibrosis | CFTR, ABCB11, ABCC5 | ALDH1A1 2608/4885CA9 1348/4885CA3 3011/4885 |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | ALDH1A1 4454/4885CA9 3397/4885CA3 4462/4885 |
| US-12497394-B2 | Fused-cyclic pyrazolone formamide compound and preparation method therefor, pharmaceutical composition and use thereof | AXL, WEE1, FLT3 | ALDH1A1 3585/4885CA9 2957/4885CA3 4391/4885 |
| US-12479857-B2 | Bax inhibitors and uses thereof | BAX, TMBIM6, BCL2 | ALDH1A1 4296/4885CA9 3830/4885CA3 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.